ANDA 201467, held by Rising Pharmaceuticals. Minocycline Hydrochloride.
As of Nov 22, 2026, ANDA 201467 (Minocycline Hydrochloride), held by Rising Pharmaceuticals, was first approved by FDA on Jul 30, 2019, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 30, 2019 | Original application | Approved | None posted |
| Minocycline HydrochlorideEQ 65MG BASE · tablet, extended release;oral | Minocycline Hydrochloride | Discontinued |
| Minocycline HydrochlorideEQ 115MG BASE · tablet, extended release;oral | Minocycline Hydrochloride | Discontinued |
| Mar 31, 2025 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 30, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters